Top Markets
Coin of the day
AstraZeneca PLC AstraZeneca PLC

AstraZeneca PLC

AZN
Rank in Stocks #5435
AstraZeneca PLC operates as a biopharmaceutical company, specializing in the... AstraZeneca PLC operates as a biopharmaceutical company, specializing in the discovery, development, manufacturing, and commercialization of prescription medications. Its comprehensive portfolio addresses diverse therapeutic areas. In oncology, key marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex. For cardiovascular, renal, and metabolism diseases, the company offers treatments such as Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR. Respiratory and immunology conditions are targeted by products like Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris. Additionally, rare diseases are treated with Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris. The company's product offerings also extend to Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for influenza; Seroquel IR/Seroquel XR for schizophrenia and bipolar disorder; Nexium and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for COVID-19. AstraZeneca serves primary and specialty care physicians globally, leveraging a network of distributors and local representative offices across the United Kingdom, the rest of Europe, the Americas, Asia, Africa, and Australasia. Strategic collaboration forms a vital component of its operations. Partnerships include an agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG for the development and commercialization of NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for transthyretin amyloidosis; Proteros Biostructures GmbH for the joint discovery of novel small molecules targeting hematological cancers; and Sierra Oncology, Inc. for the development and commercialization of AZD5153. Initially incorporated in 1992 as Zeneca Group PLC, the company adopted its current name, AstraZeneca PLC, in April 1999. It is headquartered in Cambridge, United Kingdom.
Share Price
$169.98
Last synced: 2026-09-25
Market Cap
$2.64B
Change (1 day)
0.69%
Change (1 year)
16.30%
Country
GB
Trade AstraZeneca PLC (AZN)

Category

Earnings for AstraZeneca PLC (AZN)
Earnings in Jun 2026 TTM: $12.59B
According to AstraZeneca PLC latest financial reports the company's current earnings are $12.59B. In 2024 the company made an earning of $8.69B, an increase over its 2023 earnings that were of $6.90B. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for AstraZeneca PLC from 2000 to 2026
Earnings at the end of each year
Year Earnings Change
2026 (TTM) $12.59B 1.48%
2025 $12.40B 42.70%
2024 $8.69B 25.97%
2023 $6.90B 175.85%
2022 $2.50B -1,043.77%
2021 $-265.00M -106.77%
2020 $3.92B 152.97%
2019 $1.55B -22.33%
2018 $1.99B -10.51%
2017 $2.23B -37.30%
2016 $3.55B 15.74%
2015 $3.07B 146.31%
2014 $1.25B -61.86%
2013 $3.27B -57.27%
2012 $7.65B -37.75%
2011 $12.28B 11.90%
2010 $10.98B 1.57%
2009 $10.81B 24.49%
2008 $8.68B 8.74%
2007 $7.98B -6.56%
2006 $8.54B 28.14%
2005 $6.67B 37.63%
2004 $4.84B 18.81%
2003 $4.08B -6.56%
2002 $4.36B 2.47%
2001 $4.26B 10.58%
2000 $3.85B 0.00%
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
$33.60B 166.93%
US
$25.20B 100.19%
US
$8.70B -30.88%
US
$21.39B 69.94%
CH
$5.95B -52.74%
US